BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 28, 2026
Home
»
Newsletters
» BioWorld
BioWorld
March 13, 2002
View Archived Issues
Myriad, Abbott Team In Deal To Diagnose, Treat Depression
Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today)
Read More
Ricerca Licenses Cancer Gene; CRO Embraces New Paradigm’
Read More
Classic Mutant Mouse With Multi- Neuronal Disorders Shines Light On Potential Human Manipulation
Read More
Alexion, CuraGen Seek Cancer Targets For Drug Development
Read More
Phenomix’s Forward Genetics’ Gets $32M Funding Commitment
Read More
Other News To Note
Read More
Senomyx Raises $36.8M Privately To Fund Taste, Smell Programs
Read More
